Immune checkpoint inhibitors showed remarkable anti-tumor functions in several human cancers, including programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA-4), and PD-1 ligand (PD-L1) antibodies [3,4,5]. The gene discussed is PDCD1; the disease is cancer.